Gail D Anderson

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase
    Gail D Anderson
    Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
    J Gend Specif Med 5:25-33. 2002
  2. ncbi request reprint Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    J Womens Health (Larchmt) 14:19-29. 2005
  3. doi request reprint Current oral and non-oral routes of antiepileptic drug delivery
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Adv Drug Deliv Rev 64:911-8. 2012
  4. doi request reprint Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women
    Gail D Anderson
    Department of Pharmacy, Schools of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Phytother Res 24:1442-6. 2010
  5. doi request reprint Effect of pregnancy on the pharmacokinetics of antihypertensive drugs
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Clin Pharmacokinet 48:159-68. 2009
  6. ncbi request reprint Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Clin Pharmacokinet 44:989-1008. 2005
  7. ncbi request reprint Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, 98195, USA
    Phytother Res 19:801-3. 2005
  8. ncbi request reprint Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation
    Gail D Anderson
    University of Washington, School of Pharmacy, Health Science Building H 361H, Seattle, WA 98195 7630, USA
    Expert Opin Drug Metab Toxicol 2:947-60. 2006
  9. doi request reprint Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Ther Drug Monit 30:173-80. 2008
  10. ncbi request reprint Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury
    Gail D Anderson
    Departments of Pharmacy and Neurological Surgery, Schools of Pharmacy and Medicine corrected University of Washington, Seattle, Washington 98195, USA
    Clin Pharmacokinet 46:307-18. 2007

Collaborators

Detail Information

Publications46

  1. ncbi request reprint Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase
    Gail D Anderson
    Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
    J Gend Specif Med 5:25-33. 2002
    ..However, genetics also controls the amount (or activity) of the enzymes. Sex-dependent differences have been demonstrated for several CYP isoenzymes and for UGT. Ethnicity also appears to play a role in the activity of these enzymes...
  2. ncbi request reprint Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    J Womens Health (Larchmt) 14:19-29. 2005
    ..This review highlights a few specific examples in each area in which sex differences in pharmacokinetics and pharmacodynamics are important and provides recommendations for additional needed research...
  3. doi request reprint Current oral and non-oral routes of antiepileptic drug delivery
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Adv Drug Deliv Rev 64:911-8. 2012
    ..There is a significant need for new non-oral formulations of the antiepileptic drugs when oral administration is not possible...
  4. doi request reprint Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women
    Gail D Anderson
    Department of Pharmacy, Schools of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Phytother Res 24:1442-6. 2010
    ..In conclusion, large variability in the pharmacokinetics of valerenic acid may contribute to the inconsistencies in the effect of valerian as a sleep aid...
  5. doi request reprint Effect of pregnancy on the pharmacokinetics of antihypertensive drugs
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Clin Pharmacokinet 48:159-68. 2009
    ..Higher doses and altered dosage intervals may be needed for antihypertensive drugs used in pregnant women...
  6. ncbi request reprint Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Clin Pharmacokinet 44:989-1008. 2005
    ..However, because of the limitations, more clinical, evidence-based studies are needed to fully elucidate the effects of pregnancy on the pharmacokinetics of drugs...
  7. ncbi request reprint Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, 98195, USA
    Phytother Res 19:801-3. 2005
    ....
  8. ncbi request reprint Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation
    Gail D Anderson
    University of Washington, School of Pharmacy, Health Science Building H 361H, Seattle, WA 98195 7630, USA
    Expert Opin Drug Metab Toxicol 2:947-60. 2006
    ..Knowledge of the protein binding properties of a drug can provide a quick and easy tool to estimate exposure of an infant to medication from breastfeeding...
  9. doi request reprint Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Ther Drug Monit 30:173-80. 2008
    ..Identification of experimental and clinical evidence linking functional changes associated with gene mutations to epilepsy syndromes will help provide new molecular targets for future AEDs...
  10. ncbi request reprint Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury
    Gail D Anderson
    Departments of Pharmacy and Neurological Surgery, Schools of Pharmacy and Medicine corrected University of Washington, Seattle, Washington 98195, USA
    Clin Pharmacokinet 46:307-18. 2007
    ..Valproic acid is a hepatically metabolised, low extraction-ratio drug. Therefore, unbound clearance (CL(u)) is equal to intrinsic or metabolic clearance...
  11. ncbi request reprint Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs
    Gail D Anderson
    Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
    Neurology 63:S3-8. 2004
    ..The decreased induction and inhibition effects and the lack of significant genetic polymorphism of the newer AEDs allow increased ease of use and perhaps greater safety, especially for patients taking multiple medications...
  12. ncbi request reprint Effect of valproate on hemostatic function in patients with traumatic brain injury
    Gail D Anderson
    Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA
    Epilepsy Res 57:111-9. 2003
    ..To evaluate whether valproate (VPA) resulted in laboratory or clinical evidence of a change in bleeding-related measures associated with VPA therapy in patients sustaining a traumatic brain injury...
  13. doi request reprint Optimizing pediatric dosing: a developmental pharmacologic approach
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacotherapy 29:680-90. 2009
    ..Using a pharmacokinetics-based approach, rational predictions can be made for the effects of age on drugs that undergo similar pathways of elimination, even when specific pharmacokinetic data are limited or unavailable...
  14. ncbi request reprint Children versus adults: pharmacokinetic and adverse-effect differences
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle 98195, USA
    Epilepsia 43:53-9. 2002
    ....
  15. doi request reprint Developmental pharmacokinetics
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, WA98195, USA
    Semin Pediatr Neurol 17:208-13. 2010
    ..Understanding the effects of age on pharmacokinetics can help to determine appropriate pediatric dosing in situations in which there is limited information...
  16. pmc Haptoglobin phenotype and apolipoprotein E polymorphism: relationship to posttraumatic seizures and neuropsychological functioning after traumatic brain injury
    Gail D Anderson
    Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA
    Epilepsy Behav 16:501-6. 2009
    ..In contrast to our hypothesis, those with haptoglobin 1-1 (high-affinity binder of hemoglobin) scored somewhat worse on Verbal IQ and Tapping D at 1 and 12 months after injury...
  17. pmc Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration
    Meng Li
    Department of Pharmacy, Health Science Complex H 361A, University of Washington, Seattle, WA 98195, USA
    Antimicrob Agents Chemother 53:2725-32. 2009
    ..These results suggest that the use of cranberry juice at usual quantities as prophylaxis for UTI is not likely to alter the pharmacokinetics of these two oral antibiotics...
  18. pmc A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia
    Diana M Taibi
    Department of Biobehavioral Nursing and Health Systems, School of Nursing, University of Washington, Box 357266, Seattle, WA 98195 7262, USA
    Sleep Med 10:319-28. 2009
    ..To test the effects of nightly valerian (Valeriana officinalis) extract to improve sleep of older women with insomnia...
  19. pmc Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum
    Sara Eyal
    University of Washington Department of Pharmacy, Seattle, WA 98195 7630, USA
    J Clin Pharmacol 50:1301-9. 2010
    ..Premature infants and those with kidney disease require further study. Infant exposure depends on maternal dose and decreases during the first 6 to 8 months postpartum...
  20. ncbi request reprint Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial
    Nancy R Temkin
    Department of Neurological Surgery, University of Washington, Seattle, USA
    Lancet Neurol 6:29-38. 2007
    ..We aimed to test whether treatment with magnesium favourably affects outcome in head-injured patients...
  21. pmc Is ethnicity associated with morphine's side effects in children? Morphine pharmacokinetics, analgesic response, and side effects in children having tonsillectomy
    Nathalia Jimenez
    Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA
    Paediatr Anaesth 22:669-75. 2012
    ..To examine whether morphine pharmacokinetics (PK) and/or genetic polymorphisms in opioid-related genes, underlie differences in analgesic response and side effects to morphine in Latino (L) vs non-Latino Caucasian (NL) children...
  22. pmc Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months
    Anne M Lynn
    Department of Anesthesia and Pain Management, Seattle Children s Hospital, Seattle, WA 98105, USA
    Paediatr Anaesth 21:325-34. 2011
    ..We determined the postoperative pharmacokinetics (PK), safety, and analgesic effects of ketorolac in 14 infants (aged <6 months) receiving a single intravenous (IV) administration of racemic ketorolac or placebo...
  23. ncbi request reprint Drug interaction potential of soy extract and Panax ginseng
    Gail D Anderson
    Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
    J Clin Pharmacol 43:643-8. 2003
    ..UGT2B15 was the only UGT significantly inhibited. Even though both soy extract and ginseng have been shown to activate CYP3A4 in vitro, there is a lack of an in vitro correlation with the in vivo effects...
  24. ncbi request reprint Drug-drug interactions involving membrane transporters in the human kidney
    Meng Li
    University of Washington, Department of Pharmaceutics, School of Pharmacy, Seattle, 98195, USA
    Expert Opin Drug Metab Toxicol 2:505-32. 2006
    ..In particular, the review focuses on relating cloned renal drug transporters to clinically observed drug-drug interactions. The authors' opinion on the current status and future directions of research in these areas is also offered...
  25. doi request reprint Gender differences in pharmacological response
    Gail D Anderson
    Health Science Complex H 361A, University of Washington, Seatle, Washington 98195, USA
    Int Rev Neurobiol 83:1-10. 2008
    ..There are still large gaps in our knowledge of sex differences in clinical pharmacology and significantly more research is needed...
  26. ncbi request reprint Rufinamide: a new anti-epileptic medication
    Shahin Hakimian
    University of Washington, Regional Epilepsy Center, Harborview Medical Center, Seattle, WA 98104, USA
    Expert Opin Pharmacother 8:1931-40. 2007
    ..Rufinamide has shown promise as adjunctive treatment for Lennox-Gastaut syndrome and may have some role in localization related epilepsies as well...
  27. ncbi request reprint Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics
    Anne M Lynn
    Department of Anesthesia and Pain Management, Children s Hospital and Regional Medical Center, University of Washington School of Medicine, Seattle, Washington 98105, USA
    Anesth Analg 104:1040-51, tables of contents. 2007
    ....
  28. ncbi request reprint Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum
    Mary F Hebert
    Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    J Clin Pharmacol 45:25-33. 2005
    ..Atenolol administration did not appear to change the pattern of the increase in cardiac output and the decrease in total peripheral resistance, which normally occurs during pregnancy...
  29. ncbi request reprint Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression
    Patricia Szot
    Mental Illness Research Education and Clinical Center MIRECC, VA Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA
    Brain Res Mol Brain Res 135:285-9. 2005
    ..The consequence of this suppression of IEGs following a generalized seizure may be viewed either as a neuroprotective or detrimental effect upon the brain...
  30. ncbi request reprint Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo
    Michael A Mohutsky
    Department of Medicinal Chemistry, University of Washington, Seattle, Washington 98195, USA
    Am J Ther 13:24-31. 2006
    ....
  31. ncbi request reprint Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest
    Rozenn N Lemaitre
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington 98101, USA
    Am J Med 113:711-6. 2002
    ..We sought to investigate if short-acting, inhaled beta2-adrenergic receptor agonists were associated with higher risk of primary cardiac arrest in patients with asthma or chronic obstructive pulmonary disease (COPD)...
  32. doi request reprint Optimal prevention of seizures induced by high-dose busulfan
    Andrea L Eberly
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Pharmacotherapy 28:1502-10. 2008
    ..The second-generation antiepileptic drug levetiracetam possesses the characteristics of optimal prophylaxis for busulfan-induced seizures, and early data of its efficacy are promising, although further study is needed...
  33. ncbi request reprint Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters
    Meng Li
    Department of Pharmaceutics, University of Washington, H272J, Health Sciences Building, Seattle, WA 98195 7610, USA
    Drug Metab Dispos 34:547-55. 2006
    ..2 muM for cefaclor. hPepT2, and to a lesser extent hPepT1, may play an important role in apical transport of amoxicillin and cefaclor in the renal tubule. hOAT1, in contrast, is not involved in basolateral uptake of these antibiotics...
  34. pmc The effect of progesterone dose on gene expression after traumatic brain injury
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    J Neurotrauma 28:1827-43. 2011
    ..GO analysis identified genes for the low-dose treatment involved in positive regulation of cell proliferation, innate immune response, positive regulation of anti-apoptosis, and blood vessel remodeling...
  35. ncbi request reprint Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin
    Gail D Anderson
    Department of Pharmacy, University of Washington, Seattle, USA
    Epilepsy Res 49:211-7. 2002
    ....
  36. pmc Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide
    Russell P Saneto
    Division of Pediatric Neurology, Seattle Children s Hospital University of Washington, Seattle, Washington, USA
    Ther Clin Risk Manag 5:271-80. 2009
    ..Our focus will be on the role of the new medication rufinamide in seizure reduction in patients with Lennox-Gaustaut syndrome...
  37. ncbi request reprint Digoxin therapy and the risk of primary cardiac arrest in patients with congestive heart failure: effect of mild-moderate renal impairment
    Thomas D Rea
    Cardiovascular Health Research Unit, University of Washington, Department of Medicine, Metropolitan Park, 1730 Minor Avenue, East Tower, Seattle, WA 98101, USA
    J Clin Epidemiol 56:646-50. 2003
    ..The cardiac safety of digoxin therapy for congestive heart failure (CHF) is a source of concern, especially among those with renal impairment...
  38. ncbi request reprint Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: what's the problem with generic antiepileptic drugs? A call to action
    John W Miller
    Neurology 69:1806-8. 2007
  39. ncbi request reprint Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations
    James W McAuley
    The Ohio State University College of Pharmacy, 500 West 12th Avenue, Columbus, OH 43210, USA
    Clin Pharmacokinet 41:559-79. 2002
    ..Many groups have turned their attention to women's issues in epilepsy and have developed clinical practice guidelines. Although the future holds promise in this area, many questions and the need for progress remain...
  40. ncbi request reprint The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases
    Brian T Ethell
    Department of Molecular and Cellular Pathology, Ninewells Hospital and Medical School, University of Dundee, DD1 9SY, Scotland, Dundee, UK
    Biochem Pharmacol 65:1441-9. 2003
    ..No significant inhibition of UGT1A1 or UGT1A6 by valproic acid was observed. These data indicate that valproic acid inhibition of glucuronidation reactions is not always due to simple competitive inhibition of substrates...
  41. ncbi request reprint Magnesium for neuroprotection after traumatic brain injury
    H Richard Winn
    Lancet Neurol 6:478-9. 2007
  42. ncbi request reprint Pioglitazone: effect on CYP3A4 activity
    Sandra N Nowak
    Wayne State University, Department of Pharmacy Practice, Detroit, Michigan, USA
    J Clin Pharmacol 42:1299-302. 2002
    ..Thus, administration of pioglitazone should not result in clinically significant effects on the pharmacokinetics of other CYP3A4 substrates...
  43. ncbi request reprint Voltage-dependent block of N-methyl-D-aspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of L-(+)-beta-hydroxybutyrate
    Sean D Donevan
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Epilepsia 44:1274-9. 2003
    ..In the present study, we asked whether these effects could be mediated by ionotropic glutamate or gamma-aminobutyric acidA (GABAA) receptors...
  44. ncbi request reprint Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat
    Michael R Hoane
    Restorative Neuroscience Laboratory, Department of Psychology, Southern Illinois University, Carbondale, Illinois 62901, USA
    J Neurotrauma 23:1535-48. 2006
    ..This data suggests that nicotinamide has substantial preclinical efficacy for TBI, and there appears to be some differences in the ability of the doses to improve performance in the MWM...
  45. ncbi request reprint Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy?
    Gail D Anderson
    Epilepsia 48:2372-4. 2007
  46. ncbi request reprint Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo
    Jong M Rho
    Department of Pediatrics, ZC 4482, University of California at Irvine Medical Center, Bldg 2, 3rd Floor, 101 The City Drive S, Orange, CA 92868, USA
    Epilepsia 43:358-61. 2002
    ..To investigate whether ketone bodies are directly anticonvulsant...

Research Grants2

  1. Pharmacological Optimization of Poly-Drug Therapy in Traumatic Brain Injury
    Gail Anderson; Fiscal Year: 2009
    ..This study will help to identify combinations of drugs that could be used to prevent the long-term effects. ..
  2. Pharmacological Optimization of Poly-Drug Therapy in Traumatic Brain Injury
    Michael R Hoane; Fiscal Year: 2010
    ..This study will help to identify combinations of drugs that could be used to prevent the long-term effects. ..